Nagashima Masazumi, Araki Azumi, Yanagisawa Masahiro, Komiya Atsushi, Takano Tetsuzo, Murakami Takayuki, Ikeda Ichiro
The Department of Urology, Yokohama Minami Kyousai Hospital, Japan.
Hinyokika Kiyo. 2013 Apr;59(4):213-6.
We retrospectively evaluated 23 patients who had been administered pirarubicin by intravesical instillation once weekly for 5 weeks, after undergoing surgery for upper urinary tract cancer between May 2003 and October 2008. We compared their clinical records with those of 19 patients with upper urinary tract cancer subjected to nephroureterectomy between 1998 and 2008, and who did not receive intravesical instillation of pirarubicin. This prophylactic therapy was well tolerated and contributed to reduce the rate of bladder recurrence. The non-recurrence rate at 2 years was 87.0% in the instillation group and 68.4% in the non-instillation group (P=0.0025). The overall analysis of the study population did not reveal any statistically significant risk factors of bladder recurrence.
我们回顾性评估了2003年5月至2008年10月间因上尿路癌接受手术治疗后,每周一次膀胱内灌注吡柔比星,共5周的23例患者。我们将他们的临床记录与1998年至2008年间接受肾输尿管切除术且未接受膀胱内吡柔比星灌注的19例上尿路癌患者的记录进行了比较。这种预防性治疗耐受性良好,有助于降低膀胱复发率。灌注组2年无复发率为87.0%,未灌注组为68.4%(P=0.0025)。对研究人群的总体分析未发现任何膀胱复发的统计学显著危险因素。